Allergan pulled up by FDA

Article

The FDA has sent Allergan a warning letter relating to misleading information printed in a professional journal advertisement for its ophthalmic solution, Acular LS.

The FDA has sent Allergan a warning letter relating to misleading information printed in a professional journal advertisement for its ophthalmic solution, Acular LS.

The FDA remonstrated Allergan for printing information that broadens the product's indication, presents unsubstantiated superiority claims and omits important risk information for Acular LS.

Acular LS, according to the FDA approved product labelling, is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.